Sociedad Americana de Hirudoterapia

Rosacea (Papulopustular Subtype)

Investigational adjunct for papulopustular rosacea subtype with persistent inflammatory lesions; small case series.

Tier C — InvestigationalInvestigacionalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?
Not FDA-cleared for rosacea. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for papulopustular rosacea is investigational.
¿Qué evidencia existe?
Tier C (investigational). One small case series (Wollina 2018 n=18) reports Investigator Global Assessment improvement of 1-2 grades at 12 weeks; there are no randomized controlled trials. Evidence-based therapy per AAD and 2017 ROSCO consensus: topical metronidazole, ivermectin, azelaic acid, or oral doxycycline (sub-antimicrobial 40 mg modified-release). Brimonidine for persistent erythema. Pulsed dye laser or IPL for telangiectasias.
Riesgos principales
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Worsening of facial erythema or flushing in the short term
  • Post-inflammatory hyperpigmentation, especially in darker Fitzpatrick skin
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Permanent small scars at bite sites on the face
  • Trigger of ocular rosacea if leech placed near eyelids
  • Delay of evidence-based topical or oral therapy
Quién no debería considerar esto
  • Patients with ocular rosacea (specialty management required)
  • Patients with phymatous rosacea (laser ablation or surgical management)
  • Patients with rosacea fulminans (oral isotretinoin or systemic steroid)
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients with darker Fitzpatrick skin types at high PIH risk
  • Pregnant patients
  • Patients who have not been offered topical metronidazole, ivermectin, or oral doxycycline
Qué preguntar a su clínico
  • Have I tried topical metronidazole, ivermectin, or azelaic acid for at least 12 weeks?
  • Am I a candidate for sub-antimicrobial doxycycline 40 mg modified-release?
  • Should I see an ophthalmologist for ocular rosacea symptoms?
  • Will leech placement risk worsening my flushing or burning?
  • What is the practitioner's experience with facial leech placement and PIH prevention?
  • Are leeches from an FDA-registered supplier and used only once?
  • What is the cost and is it covered by insurance? (typically not covered)
Cuándo buscar atención urgente
  • Severe sudden facial swelling with fever (rosacea fulminans — emergency)
  • New eye pain, blurred vision, or red painful eye (ocular rosacea)
  • Spreading redness, warmth, pus, or red streaks on the face (cellulitis)
  • Bleeding from a bite site lasting more than 24 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

Qué NO significa esto

  • This is NOT FDA-cleared for rosacea.
  • A single n=18 case series does NOT establish efficacy versus topical ivermectin, metronidazole, or sub-antimicrobial doxycycline.
  • It does NOT mean facial leech application is risk-free — pigment changes and scarring are facial-cosmetic concerns.
  • It does NOT substitute for evidence-based topical or oral therapy.
  • It does NOT address ocular rosacea or phymatous changes, which require specialty care.

Clinical Profile

Category
dermatological
ICD-10
L71.0, L71.8, L71.9
Safety tier
medium

Evidence Summary

The papulopustular rosacea subtype (per the 2017 ROSCO consensus) is conventionally treated with topical metronidazole, ivermectin, azelaic acid, or oral doxycycline (sub-antimicrobial 40 mg). No controlled clinical trial or published efficacy case series of leech therapy for rosacea has been reported; any use is investigational and mechanistic only. This entry is distinct from the registry's primary rosacea entry, which addresses erythematotelangiectatic disease. Post-inflammatory hyperpigmentation risk requires careful patient selection.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Wollina U (2018), n=18

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Ocular rosacea with active blepharitis or keratitis
  • Rhinophyma stage requiring surgical management
  • Patients with darker Fitzpatrick types at high PIH risk

Related Conditions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Rosacea (Papulopustular Subtype) — Hirudotherapy Evidence | ASH